Results 91 to 100 of about 30,760,747 (299)

Molecular characterization of covRS mutations in M1UK Streptococcus pyogenes

FEBS Open Bio, EarlyView.
Group A Streptococcus (GAS) acquires covRS mutations driving a hypervirulent bacterial state, frequently associated with invasive disease‐like necrotizing fasciitis. We demonstrate that the newly emerged M1UK GAS lineage can also acquire these mutations.
Jarrad Pritchard, Emma‐Jayne Proctor, Jiawa Wang, Nikolas P. Johnston, Andrew Hayes, Georgia McCorkell, Haibo Yu, Jai Tree, Mark R. Davies, Mark J. Walker, Ronald Sluyter, Stephan Brouwer, Martina L. Sanderson‐Smith   +12 more
wiley   +1 more source

EDENT1FI Master Protocol for screening of presymptomatic early-stage type 1 diabetes in children and adolescents

BMJ Open
Introduction The identification of type 1 diabetes at an early presymptomatic stage has clinical benefits. These include a reduced risk of diabetic ketoacidosis (DKA) at the clinical manifestation of the disease and a significant reduction in clinical ...
, Melanie Gündert, Anette-Gabriele Ziegler, Peter Achenbach, Olga Kordonouri, Agnieszka Szypowska, Ezio Bonifacio, Parth Narendran, Christiane Winkler, R Ribeiro, Sandra Hummel, Przemysława Jarosz-Chobot, Emanuele Bosi, R Lahesmaa, K Casteels, M Peakman, P Jarosz-Chobot, O Kordonouri, Chantal Mathieu, Vito Lampasona, J F Raposo, H Hyöty, F Pociot, João Filipe Raposo, R Berner, R Bergholdt, E Bonifacio, Flemming Pociot, B Petersen, J Van Rampelbergh, L Overbergh, B Van der Schueren, V Lampasona, C Winkler, R Coelho, O Cohen, C Mathieu, E Bosi, Stefanie Arnolds, Lut Overbergh, Zdenek Sumnik, A Koralova, G Sebastiani, Luisa Hoffmann, Mirjam Kohls, Regine Bergholdt, Bianca K Hoefelschweiger, Jurgen Vercauteren, P Gillard, J Vercauteren, A G Ziegler, P Achenbach, F Haupt, S Hummel, T Pieber, J Mader, S Moitzi, S Del Prato, B Torbeyns, Z Sumnik, O Cinek, V Neuman, B Berka, J Antvorskov, J H Klaebel, J E Laiho, F Reschke, T von dem Berge, A Hommel, A Loff, G Gemulla, N Zubizarreta, L Piemonti, F Dotta, A Szypowska, K Karczewski, E Niemoeller, M Baccara-Dinet, K Fogh, M I Buompensiere, C Hurtado del Pozo, E Latres, G Agiostratidou   +82 more
doaj   +1 more source

Effects of IGFBP4 deficiency on human preadipocyte proliferation and differentiation through the IGF1R/AKT pathway

FEBS Open Bio, EarlyView.
IGFBP4 knockdown (KD) impairs preadipocyte proliferation and is associated with IGF1R protein downregulation and attenuated AKT phosphorylation. The mechanisms by which IGFBP4 KD influences the IGF1R/AKT signaling pathway involve newly synthesized proteins and lysosomal degradation pathways. Created in BioRender.
Yujia Guo, Sandy Richter, Christoph Bach, Wieland Kiess, Anna Kirstein, Diana Le Duc, Antje Garten   +6 more
wiley   +1 more source

Trial Steering Committees in randomised controlled trials: A survey of registered clinical trials units to establish current practice and experiences [PDF]

, 2015
Background: The Medical Research Council Guidelines for Good Clinical Practice outlines a three-committee trial oversight structure - the day-to-day Trial Management Group, the Data Monitoring Committee and the Trial Steering Committee.
Conroy, Elizabeth J, Murray, Gordon, Gamble, Carrol, Lane, J Athene, Sydes, Matt R, Harman, Nicola L, Lewis, Steff C, Norrie, John   +7 more
core   +1 more source

Accurate and noninvasive prostate cancer detection using plasma‐derived extracellular vesicle RNA

FEBS Open Bio, EarlyView.
Plasma extracellular vesicles were captured with WGA‐conjugated magnetic beads and profiled for RNA biomarkers. A three‐RNA panel (NM_024955, NR_047469, and NR_002564) distinguished prostate cancer from healthy controls and benign prostatic hyperplasia, supporting a simple, noninvasive approach to improve prostate cancer detection.
Hanping Wei, Haoran Wu, Wei Feng
wiley   +1 more source

Improving ethnicity data collection and ethnic minority participation in randomised clinical trials [PDF]

UK ethnic minority patients are reported to be under-represented in clinical trials. Under-representation of any patient group within an Randomised Clinical Trial can bias trial results and subsequent extrapolation into the general population. However,
Iqbal, Gulnaz
core  

Personal benefit, or benefiting others? Deciding whether to take part in clinical trials

, 2010
Background: Participation in clinical trials is critical for the success of evidence-based healthcare. Much previous research suggests that people take part in clinical trials mostly for altruistic reasons, and that deriving personal benefit is a ...
Lorraine Smith, Louise Locock
core   +1 more source

Inadequate planning and reporting of adjudication committees in clinical trials: recommendation proposal. [PDF]

, 2009
International audienceOBJECTIVES: Adjudication committees (ACs) are recommended in randomized controlled trials (RCTs) to standardize the assessment of events.
Dechartres, Agnes, Roy, Carine, Ravaud, Philippe, Boutron, Isabelle   +3 more
core   +1 more source

TRPML1 agonist ML‐SA5 attenuates pulmonary fibroblast activation by suppressing mTOR and restoring autophagic flux

FEBS Open Bio, EarlyView.
TGF‐β1 stimulation downregulates lysosomal channel TRPML1 in pulmonary fibroblasts. The TRPML1 agonist ML‐SA5 suppressed fibroblast‐to‐myofibroblast activation and collagen production. Mechanistically, ML‐SA5 inhibited mTOR phosphorylation, restored autophagic flux, and its effects were enhanced by rapamycin (mTOR inhibitor) and reversed by MHY1485 ...
Jiatong Yao, Xiaoting Kang, Lulu Meng, Shaoxuan Zhang, Qiujie Li, Jinyu Zhou, Mengyue Xue, Chu Li, Hua Zhu, Pengzhou Hang, Jing Zhao   +10 more
wiley   +1 more source

Clinical trials

, 2017
This chapter outlines information relevant to clinical pharmacists related to clinical trials. In particular, this chapter covers clinical trial regulations and the European Clinical Trials Directive, development phases and licensing of clinical trials ...
Marc Mitchell, Nicola Stoner, Melanie Snelling, Philip Wiffen   +3 more
core   +1 more source